Zai Lab Ltd (ZLAB)

$18.66

-0.14

(-0.74%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $18.14
    $18.76
    $18.66
    downward going graph

    2.79%

    Downside

    Day's Volatility :3.3%

    Upside

    0.53%

    downward going graph
  • $13.48
    $32.60
    $18.66
    downward going graph

    27.76%

    Downside

    52 Weeks Volatility :58.65%

    Upside

    42.76%

    downward going graph

Returns

PeriodZai Lab LtdSector (Health Care)Index (Russel 2000)
3 Months
24.48%
6.4%
0.0%
6 Months
-16.7%
6.0%
0.0%
1 Year
-37.0%
8.5%
0.0%
3 Years
-88.05%
14.6%
-20.8%

Highlights

Market Capitalization
1.9B
Book Value
$7.83
Earnings Per Share (EPS)
-3.5
Wall Street Target Price
53.71
Profit Margin
-116.45%
Operating Margin TTM
-80.68%
Return On Assets TTM
-21.85%
Return On Equity TTM
-38.44%
Revenue TTM
291.1M
Revenue Per Share TTM
3.0
Quarterly Revenue Growth YOY
38.800000000000004%
Gross Profit TTM
-145.4M
EBITDA
-368.0M
Diluted Eps TTM
-3.5
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.78
EPS Estimate Next Year
-1.76
EPS Estimate Current Quarter
-0.92
EPS Estimate Next Quarter
-0.88

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Zai Lab Ltd(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
9
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 187.83%

Current $18.66
Target $53.71

Company Financials

FY18Y/Y Change
Revenue
129.5K
-
Net Income
-139.1M
↑ 176.03%
Net Profit Margin
-107.4K%
-
FY19Y/Y Change
Revenue
13.0M
↑ 9930.55%
Net Income
-183.4M
↑ 31.85%
Net Profit Margin
-1.4K%
↑ 106021.4%
FY20Y/Y Change
Revenue
49.0M
↑ 277.04%
Net Income
-298.2M
↑ 62.6%
Net Profit Margin
-609.02%
↑ 803.14%
FY21Y/Y Change
Revenue
144.3M
↑ 194.77%
Net Income
-692.4M
↑ 132.24%
Net Profit Margin
-479.82%
↑ 129.2%
FY22Y/Y Change
Revenue
215.0M
↑ 49.01%
Net Income
-482.0M
↓ 30.39%
Net Profit Margin
-224.14%
↑ 255.68%
FY23Y/Y Change
Revenue
266.7M
↑ 24.03%
Net Income
-334.6M
↓ 30.58%
Net Profit Margin
-125.46%
↑ 98.68%
Q4 FY22Q/Q Change
Revenue
62.6M
↑ 8.8%
Net Income
-26.2M
↓ 83.49%
Net Profit Margin
-41.92%
↑ 234.35%
Q1 FY23Q/Q Change
Revenue
62.8M
↑ 0.31%
Net Income
-28.8M
↑ 9.61%
Net Profit Margin
-45.81%
↓ 3.89%
Q2 FY23Q/Q Change
Revenue
68.9M
↑ 9.66%
Net Income
-120.9M
↑ 320.27%
Net Profit Margin
-175.56%
↓ 129.75%
Q3 FY23Q/Q Change
Revenue
69.2M
↑ 0.53%
Net Income
-69.2M
↓ 42.8%
Net Profit Margin
-99.89%
↑ 75.67%
Q4 FY23Q/Q Change
Revenue
65.8M
↓ 4.91%
Net Income
-95.4M
↑ 38.0%
Net Profit Margin
-144.96%
↓ 45.07%
Q1 FY24Q/Q Change
Revenue
87.1M
↑ 32.38%
Net Income
-53.5M
↓ 43.97%
Net Profit Margin
-61.36%
↑ 83.6%
FY18Y/Y Change
Total Assets
302.0M
↑ 20.97%
Total Liabilities
50.9M
↑ 251.96%
FY19Y/Y Change
Total Assets
355.2M
↑ 17.61%
Total Liabilities
60.5M
↑ 18.83%
FY20Y/Y Change
Total Assets
1.3B
↑ 265.37%
Total Liabilities
128.3M
↑ 112.08%
FY21Y/Y Change
Total Assets
1.6B
↑ 24.07%
Total Liabilities
230.0M
↑ 79.28%
FY22Y/Y Change
Total Assets
1.2B
↓ 24.21%
Total Liabilities
174.5M
↓ 24.11%
FY23Y/Y Change
Total Assets
1.0B
↓ 15.07%
Total Liabilities
240.2M
↑ 37.6%
Q4 FY22Q/Q Change
Total Assets
1.2B
↓ 6.04%
Total Liabilities
174.5M
↓ 9.4%
Q1 FY23Q/Q Change
Total Assets
1.2B
↓ 4.1%
Total Liabilities
168.8M
↓ 3.27%
Q2 FY23Q/Q Change
Total Assets
1.1B
↓ 5.44%
Total Liabilities
174.1M
↑ 3.1%
Q3 FY23Q/Q Change
Total Assets
1.0B
↓ 5.67%
Total Liabilities
162.7M
↓ 6.52%
Q4 FY23Q/Q Change
Total Assets
1.0B
↓ 0.71%
Total Liabilities
240.2M
↑ 47.61%
Q1 FY24Q/Q Change
Total Assets
988.4M
↓ 4.62%
Total Liabilities
226.3M
↓ 5.79%
FY18Y/Y Change
Operating Cash Flow
-97.5M
↑ 201.35%
Investing Cash Flow
-212.6M
↑ 1937.13%
Financing Cash Flow
144.1M
↓ 23.27%
FY19Y/Y Change
Operating Cash Flow
-191.0M
↑ 95.83%
Investing Cash Flow
-14.9M
↓ 92.99%
Financing Cash Flow
219.3M
↑ 52.14%
FY20Y/Y Change
Operating Cash Flow
-216.1M
↑ 13.11%
Investing Cash Flow
-554.8M
↑ 3625.69%
Financing Cash Flow
1.1B
↑ 416.38%
FY21Y/Y Change
Operating Cash Flow
-549.2M
↑ 154.21%
Investing Cash Flow
250.0M
↓ 145.05%
Financing Cash Flow
820.2M
↓ 27.57%
FY22Y/Y Change
Operating Cash Flow
-367.6M
↓ 33.06%
Investing Cash Flow
420.0M
↑ 68.04%
Financing Cash Flow
-1.7M
↓ 100.21%
Q4 FY22Q/Q Change
Operating Cash Flow
-109.3M
↓ 13.48%
Investing Cash Flow
-4.4M
↓ 100.77%
Financing Cash Flow
-199.0K
↓ 128.07%
Q1 FY23Q/Q Change
Operating Cash Flow
-69.3M
↓ 36.6%
Investing Cash Flow
42.7M
↓ 1076.49%
Financing Cash Flow
-3.9M
↑ 1852.76%
Q2 FY23Q/Q Change
Operating Cash Flow
-58.7M
↓ 15.28%
Investing Cash Flow
42.7M
↑ 0.0%
Financing Cash Flow
-1.5M
↓ 61.58%

Technicals Summary

Sell

Neutral

Buy

Zai Lab Ltd is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Zai Lab Ltd
Zai Lab Ltd
0.48%
-16.7%
-37.0%
-88.05%
-48.64%
Moderna, Inc.
Moderna, Inc.
-9.19%
21.5%
-4.18%
-62.27%
762.21%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.99%
12.81%
44.78%
82.21%
258.69%
Novo Nordisk A/s
Novo Nordisk A/s
-7.34%
24.69%
58.81%
196.23%
443.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.88%
11.69%
35.62%
150.46%
182.38%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Zai Lab Ltd
Zai Lab Ltd
NA
NA
NA
-2.78
-0.38
-0.22
NA
7.83
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.53
31.53
1.46
44.41
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.49
45.49
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.66
31.66
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Zai Lab Ltd
Zai Lab Ltd
Buy
$1.9B
-48.64%
NA
-116.45%
Moderna, Inc.
Moderna, Inc.
Buy
$46.5B
762.21%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.5B
258.69%
31.53
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$589.9B
443.55%
45.49
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.0B
182.38%
31.66
39.46%

Insights on Zai Lab Ltd

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 65.83M → 87.14M (in $), with an average increase of 24.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -95.42M → -53.47M (in $), with an average increase of 78.5% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 58.8% return, outperforming this stock by 95.8%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 196.2% return, outperforming this stock by 284.2%

Institutional Holdings

  • Wellington Management Company LLP

    6.72%
  • Capital World Investors

    5.73%
  • HHG PLC

    4.47%
  • Woodline Partners LP

    2.62%
  • Viking Global Investors LP

    2.07%
  • T. Rowe Price Associates, Inc.

    1.67%

Company Information

zai lab is a biopharmaceutical company dedicated to discovering, developing and commercializing innovative medicines. our vision is to address the largest unmet medical needs and transform patients’ lives around the world. we take a unique approach to combine both in-licensed products and internal r&d; to achieve a rich pipeline. we believe our drug candidates can be truly disease modifying and bring significant benefits to patients. the company was founded in 2013 by a group of industry veterans. the founders are known as pioneers in china’s fast advancing biotech industry with a proven track record for successful chinese cfda and us fda filings and approvals. our senior management team introduced fast regulatory approval pathways in china and developed a variety of partnership models with multinational pharmaceutical companies. we endeavor to conduct world class clinical development in china and beyond. zai lab has strong backing from a leading group of healthcare investors. our inve

Organization
Zai Lab Ltd
Employees
2175
CEO
Dr. Ying Du Ph.D.
Industry
Health Technology

FAQs